Cargando…

Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma

Complete pathological response (CPR) is achieved with various pretransplant locoregional treatments for hepatocellular carcinoma (HCC). This study aimed to investigate pretransplant expression of HCC tumor markers in liver transplantation (LT) recipients showing CPR. For the CPR group, 166 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min-Jae, Kang, Woo-Hyoung, Hwang, Shin, Ahn, Chul-Soo, Moon, Deok-Bog, Ha, Tae-Yong, Song, Gi-Won, Jung, Dong-Hwan, Park, Gil-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573247/
https://www.ncbi.nlm.nih.gov/pubmed/36233764
http://dx.doi.org/10.3390/jcm11195897
_version_ 1784810820915429376
author Kim, Min-Jae
Kang, Woo-Hyoung
Hwang, Shin
Ahn, Chul-Soo
Moon, Deok-Bog
Ha, Tae-Yong
Song, Gi-Won
Jung, Dong-Hwan
Park, Gil-Chun
author_facet Kim, Min-Jae
Kang, Woo-Hyoung
Hwang, Shin
Ahn, Chul-Soo
Moon, Deok-Bog
Ha, Tae-Yong
Song, Gi-Won
Jung, Dong-Hwan
Park, Gil-Chun
author_sort Kim, Min-Jae
collection PubMed
description Complete pathological response (CPR) is achieved with various pretransplant locoregional treatments for hepatocellular carcinoma (HCC). This study aimed to investigate pretransplant expression of HCC tumor markers in liver transplantation (LT) recipients showing CPR. For the CPR group, 166 patients were selected from a single-institution LT database. Two control groups of 332 patients without HCC and 184 patients with partial pathological response (PPR) were also selected. The model for end-stage liver disease score in the CPR group was 11.5 ± 7.7. The number of transcatheter arterial chemoembolization sessions before LT was one in 68 patients (14.0%), two in 38 patients (22.9%), and three or more in 60 patients (36.1%). A solitary non-viable tumor was identified in 120 (86.4%) of the explant livers and the largest tumor size was 2.4 ± 1.3 cm. Living-donor and deceased-donor LTs were performed in 152 (91.6%) and 14 (8.4%) patients, respectively. The median levels of α-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II (PIVKA-II) measured within two weeks before LT were 4.2 ng/mL and 20 mAU/mL, respectively. These tumor marker levels were comparable to those in the no-HCC control group, but much lower than those in the PPR group (p < 0.001). Receiver operating characteristic curve analysis of AFP and PIVKA-II showed no definite cutoff values for CPR in the cohort of CPR and no-HCC patients, but significant cutoffs of 6.5 ng/mL for AFP and 29 mAU/mL for PIVKA-II were obtained in the cohort of CPR and PPR patients. The 1-, 3- and 5-year HCC recurrence and overall patient survival rates of the CPR group were 5.1% and 93.3%, 7.6% and 89.6%, and 7.6% and 89.6%, respectively. These tumor recurrence rates were much lower than those in the PPR group (p < 0.001). In conclusion, the present study results suggest that normalizing AFP and PIVKA-II after locoregional treatment is indicative of CPR. However, some CPR patients showed high expression of tumor markers; thus, pretransplant values of HCC tumor markers should be interpreted with caution.
format Online
Article
Text
id pubmed-9573247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95732472022-10-17 Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma Kim, Min-Jae Kang, Woo-Hyoung Hwang, Shin Ahn, Chul-Soo Moon, Deok-Bog Ha, Tae-Yong Song, Gi-Won Jung, Dong-Hwan Park, Gil-Chun J Clin Med Article Complete pathological response (CPR) is achieved with various pretransplant locoregional treatments for hepatocellular carcinoma (HCC). This study aimed to investigate pretransplant expression of HCC tumor markers in liver transplantation (LT) recipients showing CPR. For the CPR group, 166 patients were selected from a single-institution LT database. Two control groups of 332 patients without HCC and 184 patients with partial pathological response (PPR) were also selected. The model for end-stage liver disease score in the CPR group was 11.5 ± 7.7. The number of transcatheter arterial chemoembolization sessions before LT was one in 68 patients (14.0%), two in 38 patients (22.9%), and three or more in 60 patients (36.1%). A solitary non-viable tumor was identified in 120 (86.4%) of the explant livers and the largest tumor size was 2.4 ± 1.3 cm. Living-donor and deceased-donor LTs were performed in 152 (91.6%) and 14 (8.4%) patients, respectively. The median levels of α-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II (PIVKA-II) measured within two weeks before LT were 4.2 ng/mL and 20 mAU/mL, respectively. These tumor marker levels were comparable to those in the no-HCC control group, but much lower than those in the PPR group (p < 0.001). Receiver operating characteristic curve analysis of AFP and PIVKA-II showed no definite cutoff values for CPR in the cohort of CPR and no-HCC patients, but significant cutoffs of 6.5 ng/mL for AFP and 29 mAU/mL for PIVKA-II were obtained in the cohort of CPR and PPR patients. The 1-, 3- and 5-year HCC recurrence and overall patient survival rates of the CPR group were 5.1% and 93.3%, 7.6% and 89.6%, and 7.6% and 89.6%, respectively. These tumor recurrence rates were much lower than those in the PPR group (p < 0.001). In conclusion, the present study results suggest that normalizing AFP and PIVKA-II after locoregional treatment is indicative of CPR. However, some CPR patients showed high expression of tumor markers; thus, pretransplant values of HCC tumor markers should be interpreted with caution. MDPI 2022-10-06 /pmc/articles/PMC9573247/ /pubmed/36233764 http://dx.doi.org/10.3390/jcm11195897 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Min-Jae
Kang, Woo-Hyoung
Hwang, Shin
Ahn, Chul-Soo
Moon, Deok-Bog
Ha, Tae-Yong
Song, Gi-Won
Jung, Dong-Hwan
Park, Gil-Chun
Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title_full Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title_fullStr Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title_full_unstemmed Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title_short Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma
title_sort expression patterns of tumor markers in liver transplant recipients showing complete pathological response of hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573247/
https://www.ncbi.nlm.nih.gov/pubmed/36233764
http://dx.doi.org/10.3390/jcm11195897
work_keys_str_mv AT kimminjae expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT kangwoohyoung expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT hwangshin expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT ahnchulsoo expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT moondeokbog expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT hataeyong expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT songgiwon expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT jungdonghwan expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma
AT parkgilchun expressionpatternsoftumormarkersinlivertransplantrecipientsshowingcompletepathologicalresponseofhepatocellularcarcinoma